103 related articles for article (PubMed ID: 12145699)
1. e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts.
Wang L; Seale J; Woodcock BE; Clark RE
Leukemia; 2002 Aug; 16(8):1562-3. PubMed ID: 12145699
[No Abstract] [Full Text] [Related]
2. Typical chronic myelogenous leukemia with e19a2 BCR/ABL transcript. Report of two cases.
Martínez-López J; Ayala R; Albizua Q
Haematologica; 2002 Aug; 87(8):ELT35. PubMed ID: 12161380
[No Abstract] [Full Text] [Related]
3. Molecular background of a new case of chronic myelogenous leukemia with bcr-abl chimera mRNA lacking the A2 exon.
Páldi-Haris P; Barta A; Lengyel L; Bátai A; Masszi T; Reményi P; Dénes R; Pálóczi K; Kelemen E; Földi J
Leukemia; 1994 Oct; 8(10):1791. PubMed ID: 7934177
[No Abstract] [Full Text] [Related]
4. ABL-BCR mRNAs transcribed from chromosome 9q+ in Philadelphia-chromosome-positive chronic myeloid leukaemia.
MacKenzie E; Stewart E; Birnie GD
Leukemia; 1993 May; 7(5):702-6. PubMed ID: 8483322
[TBL] [Abstract][Full Text] [Related]
5. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.
Burmeister T; Reinhardt R
Leuk Res; 2008 Apr; 32(4):579-85. PubMed ID: 17928051
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.
Liu LG; Tanaka H; Ito K; Kyo T; Ito T; Kimura A
Am J Hematol; 2003 Dec; 74(4):268-72. PubMed ID: 14635208
[TBL] [Abstract][Full Text] [Related]
7. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
8. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
[TBL] [Abstract][Full Text] [Related]
9. Differential display analysis of mRNAs in chronic myelogenous leukaemia.
el-Awady MK; Abdalla NM; Salem AM; Samir S; Nour AM
East Mediterr Health J; 2001; 7(4-5):707-15. PubMed ID: 15332769
[TBL] [Abstract][Full Text] [Related]
10. An atypical (b3/a3) junction of the bcr/abl gene lacking abl exon a2 in a patient with chronic myeloid leukemia.
Amabile M; Martinelli G; Terragna C; Montefusco V; Tabilio A; Tura S
Haematologica; 1999 Jun; 84(6):573-5. PubMed ID: 10366813
[No Abstract] [Full Text] [Related]
11. B2 exon of the BCR gene is also duplicated in some patients with CML.
Almeida TA; Cigudosa JC; Otero A; Garcia-Miranda JL
Leukemia; 1999 Apr; 13(4):645. PubMed ID: 10214875
[No Abstract] [Full Text] [Related]
12. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2.
Iwata S; Mizutani S; Nakazawa S; Yata J
Leukemia; 1994 Oct; 8(10):1696-702. PubMed ID: 7934165
[TBL] [Abstract][Full Text] [Related]
13. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
[TBL] [Abstract][Full Text] [Related]
14. bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient.
van der Plas DC; Soekarman D; van Gent AM; Grosveld G; Hagemeijer A
Leukemia; 1991 Jun; 5(6):457-61. PubMed ID: 2056770
[TBL] [Abstract][Full Text] [Related]
15. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
16. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
17. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J
J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia.
Wilson G; Frost L; Goodeve A; Vandenberghe E; Peake I; Reilly J
Blood; 1997 Apr; 89(8):3064. PubMed ID: 9108430
[No Abstract] [Full Text] [Related]
19. Comprehensive analysis of BCR/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR.
Bennour A; Ouahchi I; Moez M; Elloumi M; Khelif A; Saad A; Sennana H
Clin Lab; 2012; 58(5-6):433-9. PubMed ID: 22783572
[TBL] [Abstract][Full Text] [Related]
20. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
Martinelli G; Terragna C; Amabile M; Montefusco V; Testoni N; Ottaviani E; de Vivo A; Mianulli A; Saglio G; Tura S
Haematologica; 2000 Jan; 85(1):40-6. PubMed ID: 10629590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
